Literature DB >> 12841014

Decreased bone density in carriers and patients of an Israeli family with the osteoporosis-pseudoglioma syndrome.

Dorit Lev1, Inga Binson, A Joseph Foldes, Nathan Watemberg, Tally Lerman-Sagie.   

Abstract

BACKGROUND: The osteoporosis-pseudoglioma syndrome is a rare autosomal recessive disorder characterized by severe juvenile-onset osteoporosis and congenital or early-onset blindness. Other manifestations include muscular hypotonia, ligamentous laxity, mild mental retardation and seizures. The gene responsible was recently identified to be the low density lipoprotein receptor-related family member LRP5 on chromosome 11q11-12.
OBJECTIVE: To measure bone density in two siblings with the OPPG syndrome as well as in their family members (parents and siblings).
METHODS: Bone mineral density was determined in the lumbar spine (antero-posterior), femoral neck, two-thirds distal forearm (> 95% cortical bone) and ultradistal forearm (predominantly trabecular bone) by dual-energy X-ray absorptiometry.
RESULTS: The studies revealed osteoporotic changes both in the patients and the carriers.
CONCLUSION: The findings demonstrate that OPPG carriers have reduced bone mass, which is a risk factor for development of early osteoporotic changes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12841014

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  8 in total

Review 1.  A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-catenin Signaling in Humans and Mice.

Authors:  Kevin A Maupin; Casey J Droscha; Bart O Williams
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

2.  Reduced bone mineral density and hyaloid vasculature remnants in a consanguineous recessive FEVR family with a mutation in LRP5.

Authors:  L M Downey; H M Bottomley; E Sheridan; M Ahmed; D F Gilmour; C F Inglehearn; A Reddy; A Agrawal; J Bradbury; C Toomes
Journal:  Br J Ophthalmol       Date:  2006-09       Impact factor: 4.638

3.  Clinical and molecular findings in osteoporosis-pseudoglioma syndrome.

Authors:  Minrong Ai; Shauna Heeger; Cynthia F Bartels; Deborah K Schelling
Journal:  Am J Hum Genet       Date:  2005-09-27       Impact factor: 11.025

4.  Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG).

Authors:  C M Laine; B D Chung; M Susic; T Prescott; O Semler; T Fiskerstrand; P D'Eufemia; M Castori; M Pekkinen; E Sochett; W G Cole; C Netzer; O Mäkitie
Journal:  Eur J Hum Genet       Date:  2011-03-16       Impact factor: 4.246

5.  Clinical and biochemical response to neridronate treatment in a patient with osteoporosis-pseudoglioma syndrome (OPPG).

Authors:  M Celli; P D'Eufemia; P Persiani; A Turchetti; A Febbo; Y D'Alfonso; L Celli; A Zambrano
Journal:  Osteoporos Int       Date:  2017-09-02       Impact factor: 4.507

6.  Osteoporosis-pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates.

Authors:  Elizabeth A Streeten; Daniel McBride; Eric Puffenberger; Marc E Hoffman; Toni I Pollin; Patrick Donnelly; Paul Sack; Holmes Morton
Journal:  Bone       Date:  2008-05-07       Impact factor: 4.398

7.  Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome.

Authors:  Rajendra Kedlaya; Shreya Veera; Daniel J Horan; Rachel E Moss; Ugur M Ayturk; Christina M Jacobsen; Margot E Bowen; Chris Paszty; Matthew L Warman; Alexander G Robling
Journal:  Sci Transl Med       Date:  2013-11-13       Impact factor: 17.956

Review 8.  The ever-expanding conundrum of primary osteoporosis: aetiopathogenesis, diagnosis, and treatment.

Authors:  Stefano Stagi; Loredana Cavalli; Salvatore Seminara; Maurizio de Martino; Maria Luisa Brandi
Journal:  Ital J Pediatr       Date:  2014-06-07       Impact factor: 2.638

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.